Fuji Keizai Releases Report on Biologic Component and Material Market in Japan.

Tokyo, Japan, Mar 20, 2006 - (JCN) - Fuji Keizai announced on March 20 that it has published a report on the biologic component and material market in Japan.

The report covers 50 different biologic components and materials currently available in Japan. The market has reached 110 billion yen ($932 mil) in 2005 and is expected to grow to 169.2 billion yen ($1.4 bil) in 2010, up 54% from 2005.

By sector, the animal-derived components/materials segment will rise from 60.2 billion yen ($510 mil) in 2005 to 102.6 billion yen ($869 mil) in 2010; the plant-derived components/materials segment will climb up from 40.9 billion yen ($346 mil) in 2005 to 57.9 billion yen ($490 mil) in 2010. Meanwhile, the fungi-derived components/materials segment will shrink from 8.9 billion yen ($75 mil) in 2005 to 8.7 billion yen ($73 mil) in 2010.

In particular, the report cites five components and materials with a future growth potential; namely, coenzyme Q10, glucosamine, nattokinase, GABA (gamma-aminobutyric acid) and cauliflower fungus.

The 273-page report is available in Japanese for 105,000 yen ($890) and 115,500 yen ($978) with a supplemental CD-ROM.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.